How did XORTX Therapeutics' expenses evolve in Q4 2024?

XRTX Therapeutics' expenses in Q4 2024 were characterized by significant increases in Research and Development (R&D) and Selling, General, and Administrative (SG&A) costs, while Sales and Marketing Expenses remained relatively stable compared to the previous quarter:

1. **R&D Expenses**: The R&D expenses for XRTX Therapeutics in Q4 2024 were $7,763, which is a substantial increase from the $3,994 recorded in the previous quarter, Q3 2024. This indicates a heightened period of investment in research and development activities.
2. **SG&A Expenses**: The SG&A expenses also saw a notable rise, reaching $509,162 in Q4 2024, up from $352,731 in Q3 2024. This suggests that the company may have been expanding its operational and administrative activities, or facing increased costs associated with business growth or strategic initiatives.
3. **Sales and Marketing Expenses**: In contrast to the significant increases in R&D and SG&A, the Sales and Marketing Expenses remained relatively stable, increasing by only $1,000 from Q3 2024 to Q4 2024, reaching a total of $10,000. This could imply that the company's marketing and sales strategies did not undergo major changes during the period.

The evolution of XRTX Therapeutics' expenses in Q4 2024 reflects a company that is likely investing heavily in its product pipeline and expanding its operational footprint, while maintaining a relatively steady marketing approach.

|code|Ticker|Name|Date|R&D Expenses|Advertising and Marketing Expenses|market_code|
|---|---|---|---|---|---|---|
|XRTX|XRTX.O|XORTX Therapeutics|2024 Q1|73643||186|
|XRTX|XRTX.O|XORTX Therapeutics|2024 Q2|67683||186|
|XRTX|XRTX.O|XORTX Therapeutics|2024 Q3|34741||186|
|XRTX|XRTX.O|XORTX Therapeutics|2024 Q4|7763||186|